rs16901979: Understanding Prostate Cancer Risk at 8q24
The genetic variant rs16901979 is a single nucleotide polymorphism (SNP) located in an intergenic region on chromosome 8q24. It has been identified in research studies as a potential risk factor associated with an increased susceptibility to prostate cancer in certain populations.
What each genotype means
Increased prostate cancer risk
Research indicates that carrying this genotype is associated with a 1.5-fold increased risk for prostate cancer compared to the common genotype. This variant is located in the 8q24 region, which has been identified in multiple studies as a site of genetic susceptibility for prostate cancer. Please note that this is a statistical association observed in populations and does not constitute a medical diagnosis.
The global minor allele frequency is approximately 0.18, making this specific homozygous genotype relatively uncommon.
Increased prostate cancer risk
Carrying one copy of the risk allele is associated with a 1.5-fold increased risk for prostate cancer. This finding is based on studies of genetic markers in the 8q24 region linked to hereditary prostate cancer patterns. As this is a complex trait influenced by many factors, this information should be viewed as a statistical association rather than a definitive health outcome.
This heterozygous genotype is found in a significant portion of the population, consistent with a minor allele frequency of approximately 0.18.
Normal risk profile
This genotype is considered the baseline or normal risk profile for this specific genetic variant. It does not carry the increased risk association observed with the A allele at this position. This assessment is based on population-level genetic studies and does not account for other genetic or environmental factors that may influence prostate health.
This is the most common genotype for this variant across most studied populations.
What is rs16901979 and Where is it Located?
The variant rs16901979 is a specific change in the DNA sequence located on chromosome 8 at position 8q24. In genetics, an intergenic SNP refers to a variant that sits in the space between genes rather than within the coding sequence of a gene itself. While it does not directly alter a protein's structure, intergenic regions often contain regulatory elements that control how nearby genes are expressed. The 8q24 region is well-documented in scientific literature as a 'hotspot' for prostate cancer susceptibility, containing multiple variants that have been linked to the disease across diverse ancestral groups. Because this region is complex and highly active in regulating cellular processes, researchers study these SNPs to understand how non-coding DNA might influence the development of prostate cancer.
The Role of the 8q24 Region
The 8q24 region is widely recognized in oncology research for its association with prostate cancer. Although rs16901979 is not located within a gene, the surrounding area is known to influence the regulation of genes involved in cell growth and proliferation. Many variants in this region are thought to act as enhancers, which are DNA sequences that increase the likelihood that a gene will be transcribed. When these regulatory mechanisms are altered by variants like rs16901979, it may lead to changes in how prostate cells grow or respond to hormonal signals. Scientists continue to investigate whether these specific intergenic changes contribute to the biological pathways that lead to the formation of tumors, making this region a primary focus for understanding the hereditary components of prostate cancer.
Research Associations and Evidence Strength
Research into rs16901979 has primarily focused on its transmission patterns within families with a history of prostate cancer. Studies have observed that this variant appears more frequently in individuals who develop the disease, leading to its classification as a risk variant. However, the evidence strength for this specific SNP is considered moderate. While multiple studies have highlighted the importance of the 8q24 region, the effect size of any single SNP can vary significantly depending on the population being studied. It is important to note that genetic risk is rarely determined by one variant alone; rather, it is often the result of a complex interplay between many genetic markers and environmental factors. Current research emphasizes that while rs16901979 is a marker of interest, it should be viewed as part of a broader genetic landscape rather than a definitive diagnostic tool.
Population Frequency and Variability
The frequency of the rs16901979 variant is known to be variable across different global populations. Genetic variants often show different distribution patterns based on ancestral background, which can influence how strongly a variant is associated with a disease in a specific group. Some studies have indicated that risk variants at 8q24 show consistent effects across various ethnic groups, while others suggest that the prevalence and impact of these markers may differ. Because of this variability, researchers stress the need for multi-ancestry studies to ensure that genetic risk assessments are accurate for everyone. If you are interested in your own genetic profile, it is helpful to understand that population-level data provides a statistical context, but it does not predict individual health outcomes with certainty.
What You Can and Cannot Do With This Information
Understanding your genetic variants can be an educational experience, but it is not a substitute for professional medical advice. You cannot use information about rs16901979 to diagnose yourself with prostate cancer or to predict your future health with absolute certainty. Genetic associations are statistical observations made across large groups of people, not individual medical predictions. If you have a family history of prostate cancer or are concerned about your risk, the most important step is to consult with a healthcare provider or a genetic counselor. They can help you interpret your family history, discuss appropriate screening schedules, and provide guidance based on your specific clinical profile. Never make changes to your health management or screening routine based solely on genetic data without first discussing it with a qualified medical professional.
How common is this variant?
The frequency of the rs16901979 variant is variable across different ancestral populations, and current research notes that its prevalence and impact require further study in diverse groups.
Frequently asked questions
Is rs16901979 a diagnostic test for prostate cancer?
No, rs16901979 is not a diagnostic test. It is a genetic marker associated with a statistical increase in risk, but it cannot determine if you have or will develop prostate cancer.
Should I be worried if I have the A allele?
Having a specific allele does not mean you will develop a disease. Genetic risk is complex, and many factors, including family history and lifestyle, play a much larger role in your overall health.
How can I find out if I have this variant?
This variant may be included in some direct-to-consumer genetic testing reports or clinical genomic studies. You should review any such reports with a healthcare professional to understand their clinical relevance.
What should I do if I have a family history of prostate cancer?
If you have a family history, you should speak with your doctor about your risk factors. They can recommend appropriate screening tests, such as PSA tests, based on your personal and family medical history.
Sources & further reading
Educational information only, last refreshed 9/21/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16901979?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants
A newly identified variant near the FTO gene associated with BMI, identified through non-additive genetic modeling.
This variant shows major significance in predicting Type 2 diabetes and cardiovascular condition risk in individuals with metabolic syndrome.
This variant is associated with quantitative facial wrinkle area and perceived facial aging, potentially regulating the ADCYAP1 gene.
This intronic variant near TRIB1 is associated with circulating lipid levels, including triglycerides and LDL cholesterol, and is linked to coronary artery disease risk.
This variant is a clinically relevant marker in Asian populations often analyzed for its impact on drug transport and metabolic fitness.
Located between HLA-DRB1 and HLA-DQA1, this variant is associated with an increased risk of non-Hodgkin's lymphoma in Hepatitis C patients.